Evidence map›Paper›PMID 39299943›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2025

An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries.

Giovanny Leon, Christophe Carbonel, Aparajit Rampuria, Ravindra Singh Rajpoot, Parth Joshi, Panos Kanavos

Abstract read
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Giovanny LeonPrice Governance and Negotiations, Value and Access and Commercial Development, Novartis Pharma AG, Basel, Switzerland.
Christophe CarbonelPrice Governance and Negotiations, Value and Access and Commercial Development, Novartis Pharma AG, Basel, Switzerland.
Aparajit RampuriaPrice Governance and Negotiations, Value and Access and Commercial Development, Novartis Pharma AG, Basel, Switzerland.
Ravindra Singh RajpootValue and Access, Novartis Healthcare Private Limited, Hyderabad, India.
Parth JoshiValue and Access, Novartis Healthcare Private Limited, Hyderabad, India.
Panos KanavosDepartment of Health Policy and Medical Technology Research Group-LSE Health, The London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK. p.g.kanavos@lse.ac.uk.ORCID http://orcid.org/0000-0001-9518-3089

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper analyses the structure of and variability in taxation and prescription drug distribution policies and quantifies the impact of such policies on the cost of prescription drugs to health systems in 35 countries. Taxes on prescription drugs remain highly prevalent (83% of the sample) although 63% of the sample countries implement a lower than standard VAT rate. Three remuneration types of the wholesale and retail distribution chain have been identified. Wholesale and retail distributors are remunerated on a regressive mark-up basis, which is price-dependent, although fixed fees and fixed percentages, which are non-price dependent, are also highly prevalent. Price component analysis for three groups of products classed as high-, medium- and low-priced suggests that mark-ups plus taxes varied significantly across countries and products, and ranged from 5% to 187% of ex-factory prices. Average margins also vary significantly by countries and products ranging 5-65% of retail prices. The cost of distribution and taxation contributes significantly to prescription drug costs for health systems. Although distribution chain remuneration raises efficiency and overall affordability questions, these need to be considered together with the regulatory framework shaping market structure of the distribution chain, as well as any prevailing horizontal and vertical integration policies. The overall cost of prescription drugs could be reduced immediately by eliminating taxation; this could go some way to alleviate fiscal pressures on health budgets, whilst avoiding resource re-allocation from health to other sectors.

Indexed as

Drug CostsHealth PolicyPrescription DrugsRemunerationTaxesCommerceHumansPrescription DrugsDrug distributionDrug taxationImpact assessmentNational drug policyRegressive mark upsRegulationSupply systems

Identifiers

PMID39299943
PMCPMC11937219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.